Anastrozole
Product Images NDC 67877-171

6 FDA label images from Ascend Laboratories, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 67877-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Anastrozole Chemical Structure (Anastrozole Chemical Structure)

Anastrozole Chemical Structure (Anastrozole Chemical Structure)
Chemical structure of anastrozole showing a triazole ring attached to a substituted benzene ring with two cyanomethyl groups and methyl groups. The structure is depicted in a two-dimensional diagram format.*
FDA Label Image

Ascend Anastrozole Tablets (1 mg product label)

Ascend Anastrozole Tablets (1 mg product label)
Anastrozole tablets 1 mg label from Ascend Laboratories, LLC, containing 30 tablets per bottle. The label indicates prescription use only and includes storage instructions at controlled room temperature. The product is manufactured by Natco Pharma Limited, India, for Ascend Laboratories in Montvale, NJ. The NDC number 67877-171-30 is displayed along with lot and expiration date fields.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
Kaplan Meier survival curve comparing disease-free survival in months for patients randomized to Anastrozole tablets or Tamoxifen monotherapy in the ATAC trial. The graph shows proportion alive and disease-free on the y-axis, and includes number of patients at risk over time for both treatments.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A survival curve chart showing disease-free survival over months for hormone receptor-positive patients randomized to Anastrozole or Tamoxifen in the ATAC trial. The y-axis represents the proportion alive and disease-free, and the x-axis shows disease-free survival in months up to 90 months. Patient risk numbers for each treatment group are listed below the x-axis.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A Kaplan-Meier curve showing the probability of time to disease progression in months for patients treated with Anastrozole compared to Tamoxifen. The y-axis represents the proportion of patients not progressing, and the x-axis represents time in months. The chart includes patient risk numbers at various time points.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
Kaplan-Meier probability chart showing time to progression for randomized patients in Trial 0027, comparing Anastrozole and Tamoxifen treatments. The graph plots proportion not progressing over time in months, with patient numbers at risk listed below.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.